IN8BIO, Inc.
INAB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001740279
No open-market purchases or sales by IN8BIO, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $5.35M in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding IN8BIO, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 26 | 26 | 0 |
| Shares | 7.63M | 30.0M | +22.4M (+293.8%) |
| Value | $2.06M | $7.72M | +$5.66M (+275.1%) |
New holders (5)
Institutions that held IN8BIO, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BIOS Capital Management, LP | 8,600,001 | $2.21M | 2.35% |
| Franklin Resources Inc | 5,696,202 | $1.47M | 0.00% |
| XTX Topco Ltd | 42,399 | $10.9K | 0.00% |
| Goldman Sachs Group Inc | 10,193 | $2.62K | 0.00% |
| SBI Securities Co., Ltd. | 7 | $2 | 0.00% |
Sold out (5)
Institutions that held IN8BIO, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Ensign Peak Advisors, Inc | 829,176 | $223.9K |
| Texas Capital Bank Wealth Management Services Inc | 78,624 | $21.2K |
| Voss Capital, LLC | 64,000 | $17.3K |
| HRT Financial LP | 11,252 | $3.00K |
| Barclays PLC | 102 | $28 |